The NCRC AD case collection is one of the largest in the world, and has been used for identification of many genes involved in AD pathogenesis, including the filaggrin discovery.
Consultant Dermatologist, Professor
Alan graduated in Medicine from Queen’s University Belfast (QUB) in 1991. In 1998, he was awarded a research doctorate (MD) in Human Genetics, also from QUB. He completed Dermatology Training in Belfast in July 1999, followed by fellowships in Great Ormond Street Children’s Hospital, and Children’s Memorial Hospital Chicago, where he was a Fulbright Scholar.
He was appointed Consultant Dermatologist (Attending Physician) in Children’s Health Ireland at Crumlin (CHI at Crumlin) and St. James’s Hospital, Dublin, Ireland in October 2002. The CHI at Crumlin department provides specialist clinics in severe atopic dermatitis, vascular malformations, laser treatments, and genetic skin diseases with more than 10 000 secondary and tertiary paediatric attendances per annum. His adult clinics provide a service for complex atopic dermatitis and genodermatoses.
He is Professor in Dermatology, Trinity College Dublin. His research interests are in epithelial genetics, disease mechanisms in, and therapy of, atopic dermatitis. His work on the genetics of atopic dermatitis with long term collaborative partner Irwin McLean has helped refocus attention on the role of the skin barrier in the pathogenesis of this disease and of allergic disease in general. He is funded by the National Children’s Research Centre and the Wellcome Trust, and has attracted approximately €11M funding to date.
Consultant Dermatologist, Professor
The NCRC AD case collection is one of the largest in the world, and has been used for identification of many genes involved in AD pathogenesis, including the filaggrin discovery.
We have long standing research programs examining skin barrier function in atopic dermatitis. We use non-invasive techniques such as Raman spectroscopy and tape stripping to gain mechanistic and functional insights into AD pathogenesis.
We provide care for a large cohort of patients with vascular anomalies and overgrowth syndromes. We collaborate with investigators in Belgium on gene identification and with companies developing novel therapies.
For the last two decades we have worked on identification of causal genetic mutations in children with genetic skin disorders.
The list of publications below is automatically derived from MEDLINE/PubMed. As a result, there may be incorrect or missing publications.
Ismail M, Doelger E, Eckert D, Irvine AD, Chu AD, Teixeira HD, Liu W, Nader A, 2023 May 26, Population Pharmacokinetic and Exposure-Response Modeling to Inform Upadacitinib Dose Selection in Adolescent and Adult Patients with Atopic Dermatitis. Br J Clin Pharmacol, DOI: 10.1111/bcp.15803 |
Flohr C, Irvine AD, Cork MJ, Simpson EL, Wollenberg A, Deleuran M, Praestgaard A, Thomas RB, Rossi AB, 2023 Apr 30, Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis. Br J Dermatol, DOI: 10.1093/bjd/ljad124 |
Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD, 2023 May 1, Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol, DOI: 10.1001/jamadermatol.2023.0391 |
Bieber T, Thyssen JP, Irvine AD, Tsunemi Y, Chen YF, Sun L, Schloebe A, Riedl E, Cork MJ, 2023 Apr 10, Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis. Clin Exp Dermatol, DOI: 10.1093/ced/llad129 |
Irvine AD, Hourihane JOB, STOP-AD Team, 2023 Apr, Reply to correspondence "Food allergens to emollients". Allergy, DOI: 10.1111/all.15651 |
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J, ADvocate1 and ADvocate2 Investigators, 2023 Mar 23, Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med, DOI: 10.1056/NEJMoa2206714 |
Duggan C, Irvine AD, O'B Hourihane J, Kiely ME, Murray DM, 2023 Feb 25, ASQ-3 and BSID-III's concurrent validity and predictive ability of cognitive outcome at 5 years. Pediatr Res, DOI: 10.1038/s41390-023-02528-y |
Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E, 2023 Feb, Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open, DOI: 10.1136/rmdopen-2022-002735 |
Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Lockshin B, Irvine AD, Kim MB, Kabashima K, Chen Z, Lu Y, Bansal A, Rossi AB, Shabbir A, 2023 Mar 1, Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials. JAMA Dermatol, DOI: 10.1001/jamadermatol.2022.6192 |
Nousbeck J, McAleer MA, Irvine AD, 2023 Mar, Peripheral Blood Gene Expression Profile of Infants with Atopic Dermatitis. JID Innov, DOI: 10.1016/j.xjidi.2022.100165 |
Walsh C, Leavey G, Mc Laughlin M, Paller AS, Irvine AD, Browne F, Mellerio JE, Bewley A, 2023 Jan 18, Novel mixed-method, inclusive protocol involving global key stakeholders, including carers as experts, to co-develop relevant Caregiver-Reported Outcome Domains (CRODs) in skin disease. BMJ Open, DOI: 10.1136/bmjopen-2022-068893 |
Gabaston J, Buffeteau T, Irvine AD, Gambetta G, Mérillon JM, Waffo-Téguo P, 2023 Mar 30, Chiral analysis of E-ε-viniferin enantiomers, towards a new chemotaxonomic marker of the vine. J Sci Food Agric, DOI: 10.1002/jsfa.12444 |
Beck LA, Bieber T, Weidinger S, Tauber M, Saeki H, Irvine AD, Eichenfield LF, Werfel T, Arlert P, Jiang L, Røpke M, Paller AS, 2023 Apr, Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. J Am Acad Dermatol, DOI: 10.1016/j.jaad.2022.11.047 |
Bosma AL, Ouwerkerk W, Heidema MJ, Prieto-Merino D, Ardern-Jones MR, Beattie P, Brown SJ, Ingram JR, Irvine AD, Ogg G, Patel P, Reynolds NJ, Hearn RMR, Wan M, Warren RB, Woolf RT, Hyseni AM, Gerbens LAA, Spuls PI, Flohr C, Middelkamp-Hup MA, TREAT NL registry and UK-Irish A-STAR Study Groups, 2023 Mar, Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. JAAD Int, DOI: 10.1016/j.jdin.2022.09.006 |
Ghaffarpour N, Baselga E, Boon LM, Diociaiuti A, Dompmartin A, Dvorakova V, El Hachem M, Gasparella P, Haxhija E, Kyrklund K, Irvine AD, Kapp FG, Rößler J, Salminen P, van den Bosch C, van der Vleuten C, Kool LS, Vikkula M, 2022 Dec, The VASCERN-VASCA working group diagnostic and management pathways for lymphatic malformations. Eur J Med Genet, DOI: 10.1016/j.ejmg.2022.104637 |
Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, Chih-Ho Hong H, Hendrickson B, Dilley D, Tenorio AR, Ladizinski B, Chu AD, Liu J, Irvine AD, 2023 Jan, Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies. J Allergy Clin Immunol, DOI: 10.1016/j.jaci.2022.09.023 |
Musters AH, Broderick C, Prieto-Merino D, Chiricozzi A, Damiani G, Peris K, Dhar S, De A, Freeman E, Arents BWM, Burton T, Bosma ALL, Chi CC, Fletcher G, Drucker AM, Kabashima K, de Monchy EF, Panda M, Wall DR, Vestergaard C, Mahé E, Bonzano L, Kattach L, Napolitano M, Ordoñez-Rubiano MF, Haufe E, Patruno C, Irvine AD, Spuls PI, Flohr C, 2023 Feb, The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry. J Eur Acad Dermatol Venereol, DOI: 10.1111/jdv.18613 |
Bieber T, Feist E, Irvine AD, Harigai M, Haladyj E, Ball S, Deberdt W, Issa M, Grond S, Taylor PC, 2022 Nov, A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19. Adv Ther, DOI: 10.1007/s12325-022-02281-4 |
Ní Chaoimh C, Lad D, Nico C, Puppels GJ, Wong XFCC, Common JE, Murray DM, Irvine AD, Hourihane JO, 2023 Apr, Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants-The STOP-AD randomised controlled trial. Allergy, DOI: 10.1111/all.15491 |
O'Connor C, Livingstone V, Hourihane JOB, Irvine AD, Boylan G, Murray D, 2022 Nov, Parental atopy and risk of atopic dermatitis in the first two years of life in the BASELINE birth cohort study. Pediatr Dermatol, DOI: 10.1111/pde.15090 |
Miyano T, Irvine AD, Tanaka RJ, 2022 May, Model-Based Meta-Analysis to Optimize Staphylococcus aureus‒Targeted Therapies for Atopic Dermatitis. JID Innov, DOI: 10.1016/j.xjidi.2022.100110 |
O'Connor C, Irvine AD, Murray D, Murphy M, O'B Hourihane J, Boylan G, 2022 Jun 18, Study protocol: assessing SleeP IN infants with early-onset atopic Dermatitis by Longitudinal Evaluation (The SPINDLE study). BMC Pediatr, DOI: 10.1186/s12887-022-03382-3 |
Werfel T, Irvine AD, Bangert C, Seneschal J, Grond S, Cardillo T, Brinker D, Zhong J, Riedl E, Wollenberg A, 2022 Sep, An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol, DOI: 10.1111/jdv.18193 |
Diociaiuti A, Baselga E, Boon LM, Dompmartin A, Dvorakova V, El Hachem M, Gasparella P, Haxhija E, Ghaffarpour N, Kyrklund K, Irvine AD, Kapp FG, Rößler J, Salminen P, van den Bosch C, van der Vleuten C, Kool LS, Vikkula M, 2022 Jun, The VASCERN-VASCA working group diagnostic and management pathways for severe and/or rare infantile hemangiomas. Eur J Med Genet, DOI: 10.1016/j.ejmg.2022.104517 |
Stefanovic N, Fitzmaurice CJ, Ormond P, Irvine AD, Barry RB, 2022 Sep, Risk factors for distant metastasis in cutaneous squamous cell carcinoma. Br J Dermatol, DOI: 10.1111/bjd.21250 |
Mussa A, Leoni C, Iacoviello M, Carli D, Ranieri C, Pantaleo A, Buonuomo PS, Bagnulo R, Ferrero GB, Bartuli A, Melis D, Maitz S, Loconte DC, Turchiano A, Piglionica M, De Luisi A, Susca FC, Bukvic N, Forleo C, Selicorni A, Zampino G, Onesimo R, Cappuccio G, Garavelli L, Novelli C, Memo L, Morando C, Della Monica M, Accadia M, Capurso M, Piscopo C, Cereda A, Di Giacomo MC, Saletti V, Spinelli AM, Lastella P, Tenconi R, Dvorakova V, Irvine AD, Resta N, 2023 Feb, Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants. J Med Genet, DOI: 10.1136/jmedgenet-2021-108093 |
Paller AS, Guttman-Yassky E, Schuttelaar MLA, Irvine AD, Baselga E, Kataoka Y, Antila M, de Bruin-Weller MS, Marcoux D, Abramova A, Rizova E, Liu C, Zhang A, 2022 Nov, Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry. J Am Acad Dermatol, DOI: 10.1016/j.jaad.2022.01.018 |
Kezic S, McAleer MA, Jakasa I, Goorden SMI, der Vlugt KG, Beers-Stet FS, Meijer J, Roelofsen J, Nieman MM, van Kuilenburg ABP, Irvine AD, 2022 Jun, Children with atopic dermatitis show increased activity of β-glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to the local cytokine milieu. Br J Dermatol, DOI: 10.1111/bjd.20979 |
Silverberg JI, Simpson EL, Armstrong AW, de Bruin-Weller MS, Irvine AD, Reich K, 2022 Jan, Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol, DOI: 10.1007/s40257-021-00639-y |
Holm A, Te Loo M, Schultze Kool L, Salminen P, Celis V, Baselga E, Duignan S, Dvorakova V, Irvine AD, Boon LM, Vikkula M, Ghaffarpour N, Niemeyer CM, Rössler J, Kapp FG, 2021, Efficacy of Sirolimus in Patients Requiring Tracheostomy for Life-Threatening Lymphatic Malformation of the Head and Neck: A Report From the European Reference Network. Front Pediatr, DOI: 10.3389/fped.2021.697960 |
Bradshaw LE, Haines RH, Thomas KS, Chalmers JR, Irvine AD, Williams HC, Brown SJ, 2021 Nov, Clinical examination for hyperlinear palms to determine filaggrin genotype: A diagnostic test accuracy study. Clin Exp Allergy, DOI: 10.1111/cea.14025 |
Freeman EE, Chamberlin GC, McMahon DE, Hruza GJ, Wall D, Meah N, Sinclair R, Balogh EA, Feldman SR, Lowes MA, Marzano AV, Naik HB, Castelo-Soccio L, Lara-Corrales I, Cordoro KM, Mahil SK, Griffiths CEM, Smith CH, Irvine AD, Spuls PI, Flohr C, French LE, 2021 Oct, Dermatology COVID-19 Registries: Updates and Future Directions. Dermatol Clin, DOI: 10.1016/j.det.2021.05.013 |
Wall D, Alhusayen R, Arents B, Apfelbacher C, Balogh EA, Bokhari L, Bloem M, Bosma AL, Burton T, Castelo-Soccio L, Fagan N, Feldman SR, Fletcher G, Flohr C, Freeman E, French LE, Griffiths CEM, Hruza GJ, Ingram JR, Kappelman MD, Lara-Corrales I, Lim HW, Meah N, McMahon DE, Mahil SK, McNicoll I, Musters A, Naik HB, Sinclair R, Smith CH, Spuls P, Tobin DJ, York K, Irvine AD, 2021 May-Jun, Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. Clin Dermatol, DOI: 10.1016/j.clindermatol.2021.01.018 |
Xing C, Kanchwala M, Rios JJ, Hyatt T, Wang RC, Tran A, Dougherty I, Tovar-Garza A, Purnadi C, Kumar MG, Berk D, Shinawi M, Irvine AD, Toledo-Bahena M, Agim NG, Glass DA 2nd, 2021 Aug, Biallelic variants in RNU12 cause CDAGS syndrome. Hum Mutat, DOI: 10.1002/humu.24239 |
Stefanovic N, Irvine AD, Flohr C, 2021, The Role of the Environment and Exposome in Atopic Dermatitis. Curr Treat Options Allergy, DOI: 10.1007/s40521-021-00289-9 |
Deleuran M, Marcoux D, Bruin-Weller MS, Irvine AD, Baselga E, Ahn K, Castro AP, Bansal A, Chao J, Bégo-Le-Bagousse G, Rossi AB, 2021 Jul 15, Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use. Acta Derm Venereol, DOI: 10.2340/00015555-3848 |
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaçi D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD, 2021 Jun 5, Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet, DOI: 10.1016/S0140-6736(21)00588-2 |
Fagan N, Meah N, York K, Bokhari L, Fletcher G, Chen G, Tobin DJ, Messenger A, Irvine AD, Sinclair R, Wall D, 2021 Jan-Feb, Shedding light on therapeutics in alopecia and their relevance to COVID-19. Clin Dermatol, DOI: 10.1016/j.clindermatol.2020.12.015 |
Miyano T, Irvine AD, Tanaka RJ, 2022 Feb, A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis. Allergy, DOI: 10.1111/all.14870 |
Luger T, Paller AS, Irvine AD, Sidbury R, Eichenfield LF, Werfel T, Bieber T, 2021 Jul, Topical therapy of atopic dermatitis with a focus on pimecrolimus. J Eur Acad Dermatol Venereol, DOI: 10.1111/jdv.17272 |
Doherty AM, Colleran GC, Durcan L, Irvine AD, Barrett E, 2022 Feb, A pilot study of burnout and long covid in senior specialist doctors. Ir J Med Sci, DOI: 10.1007/s11845-021-02594-3 |
Wall D, Meah N, York K, Bhoyrul B, Bokhari L, Abraham LS, Adams R, Bergfeld W, Betz RC, Blume-Peytavi U, Callender V, Campbell C, Chambers J, Chen G, Chitreddy V, Cotsarelis G, Craiglow B, Dhurat R, Dlova N, Donovan J, Duque-Estrada B, Eisman S, Ellison A, Farrant P, Barberá JF, Gadzhigoroeva A, Grimalt R, Harries M, Hordinsky M, Irvine AD, Jolliffe V, Jones L, King B, Lee WS, Lortkipanidze N, McMichael A, Messenger A, Mirmirani P, Olsen E, Orlow SJ, Ovcharenko Y, Piraccini BM, Pirmez R, Rakowska A, Reygagne P, Riley M, Rudnicka L, Saceda Corralo D, Shapiro J, Sharma P, Silyuk T, Kaiumov S, Tobin DJ, Tosti A, Vañó-Galván S, Vogt A, Wade M, Yip L, Zlotogorski A, Zhou C, Sinclair R, 2021 Apr 1, A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS). JAMA Dermatol, DOI: 10.1001/jamadermatol.2020.5839 |
Mulick AR, Mansfield KE, Silverwood RJ, Budu-Aggrey A, Roberts A, Custovic A, Pearce N, Irvine AD, Smeeth L, Abuabara K, Langan SM, 2021 Sep, Four childhood atopic dermatitis subtypes identified from trajectory and severity of disease and internally validated in a large UK birth cohort. Br J Dermatol, DOI: 10.1111/bjd.19885 |
Forde K, Resta N, Ranieri C, Rea D, Kubassova O, Hinton M, Andrews KA, Semple R, Irvine AD, Dvorakova V, 2021 Feb 27, Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome. Orphanet J Rare Dis, DOI: 10.1186/s13023-021-01745-0 |
McCarthy EK, Murray DM, Hourihane JOB, Kenny LC, Irvine AD, Kiely ME, 2021 Apr 6, Behavioral consequences at 5 y of neonatal iron deficiency in a low-risk maternal-infant cohort. Am J Clin Nutr, DOI: 10.1093/ajcn/nqaa367 |
Hotz A, Kopp J, Bourrat E, Oji V, Komlosi K, Giehl K, Bouadjar B, Bygum A, Tantcheva-Poor I, Hellström Pigg M, Has C, Yang Z, Irvine AD, Betz RC, Zambruno G, Tadini G, Süßmuth K, Gruber R, Schmuth M, Mazereeuw-Hautier J, Jonca N, Guez S, Brena M, Hernandez-Martin A, van den Akker P, Bolling MC, Hannula-Jouppi K, Zimmer AD, Alter S, Vahlquist A, Fischer J, 2021 Jan 9, Meta-Analysis of Mutations in ALOX12B or ALOXE3 Identified in a Large Cohort of 224 Patients. Genes (Basel), DOI: 10.3390/genes12010080 |
Towell AM, Feuillie C, Vitry P, Da Costa TM, Mathelié-Guinlet M, Kezic S, Fleury OM, McAleer MA, Dufrêne YF, Irvine AD, Geoghegan JA, 2021 Jan 5, Staphylococcus aureus binds to the N-terminal region of corneodesmosin to adhere to the stratum corneum in atopic dermatitis. Proc Natl Acad Sci U S A, DOI: 10.1073/pnas.2014444118 |
McAleer MA, Jakasa I, Stefanovic N, McLean WHI, Kezic S, Irvine AD, 2021 Jul, Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis. Br J Dermatol, DOI: 10.1111/bjd.19703 |
Siegels D, Heratizadeh A, Abraham S, Binnmyr J, Brockow K, Irvine AD, Halken S, Mortz CG, Flohr C, Schmid-Grendelmeier P, Van der Poel LA, Muraro A, Weidinger S, Werfel T, Schmitt J, European Academy of Allergy, Clinical Immunology Atopic Dermatitis Guideline group, 2021 Apr, Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. Allergy, DOI: 10.1111/all.14631 |
Delles C, Dayan CM, Dominiczak AF, Donnelly SC, Irvine AD, 2021 Feb 18, Announcing the first AoP webinar: 'Can evidence-based medicine survive in a pandemic?'. QJM, DOI: 10.1093/qjmed/hcaa287 |
Boggs JME, Irvine AD, 2021 Jan, PLACK syndrome resulting from a novel homozygous variant in CAST. Pediatr Dermatol, DOI: 10.1111/pde.14383 |
Haftek M, McAleer MA, Jakasa I, McLean WI, Kezic S, Irvine AD, 2020, Changes in nano-mechanical properties of human epidermal cornified cells in children with atopic dermatitis. Wellcome Open Res, DOI: 10.12688/wellcomeopenres.15729.2 |
Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Asz-Sigall D, Bergfeld WF, Betz RC, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Donovan J, Eisman S, Farrant P, Green J, Grimalt R, Harries M, Hordinsky M, Irvine AD, Itami S, Jolliffe V, King B, Lee WS, McMichael A, Messenger A, Mirmirani P, Olsen E, Orlow SJ, Piraccini BM, Rakowska A, Reygagne P, Roberts JL, Rudnicka L, Shapiro J, Sharma P, Tosti A, Vogt A, Wade M, Yip L, Zlotogorski A, Sinclair RD, 2021 Jun, The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. J Am Acad Dermatol, DOI: 10.1016/j.jaad.2020.09.028 |
Alsaleemi A, O'Connor C, Irvine AD, Leahy TR, 2020 Nov, Topical cidofovir for the treatment of recalcitrant viral warts and molluscum contagiosum in Jacobsen syndrome. Pediatr Dermatol, DOI: 10.1111/pde.14355 |
Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, Ruzek MC, Slivka PF, McGettrick AF, Banahan K, Hughes MM, Irvine AD, Fischer R, O'Neill LAJ, 2020 Sep 1, The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation. Cell Metab, DOI: 10.1016/j.cmet.2020.07.016 |
Onoufriadis A, Cabezas A, Ng JCF, Canales J, Costas MJ, Ribeiro JM, Rodrigues JR, McAleer MA, Castelo-Soccio L, Simpson MA, Fraternali F, Irvine AD, Cameselle JC, McGrath JA, 2021 May, Autosomal recessive hypotrichosis with loose anagen hairs associated with TKFC mutations. Br J Dermatol, DOI: 10.1111/bjd.19481 |
Langan SM, Irvine AD, Weidinger S, 2020 Aug 1, Atopic dermatitis. Lancet, DOI: 10.1016/S0140-6736(20)31286-1 |
Cunningham L, Dvorakova V, Browne F, Irvine AD, 2021 Mar, High-dose bilastine for the treatment of BASCULE syndrome. Clin Exp Dermatol, DOI: 10.1111/ced.14377 |
Freeman EE, McMahon DE, Hruza GJ, Irvine AD, Spuls PI, Smith CH, Mahil SK, Castelo-Soccio L, Cordoro KM, Lara-Corrales I, Naik HB, Alhusayen R, Ingram JR, Feldman SR, Balogh EA, Kappelman MD, Wall D, Meah N, Sinclair R, Beylot-Barry M, Fitzgerald M, French LE, Lim HW, Griffiths CEM, Flohr C, 2020 Sep, International collaboration and rapid harmonization across dermatologic COVID-19 registries. J Am Acad Dermatol, DOI: 10.1016/j.jaad.2020.06.050 |
Please visit PubMed for more information on Alan Irvine's publications
Name: | Professor Irwin McLean |
Department | Human Genetics |
Institution: | University of Dundee |
Country: | UK |
Name: | Dr Sanja Kezic |
Department | Toxicology |
Institution: | Academic Medicine Centre Amsterdam |
Country: | Netherlands |
Name: | Professor Stephan Weidinger |
Department | Dermatology |
Institution: | Kiel |
Country: | Germany |
Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
---|---|---|---|---|
TREAT | A randomised clinical trial to assess the treatment safety and efficacy of oral methotrexate (MTX) vs ciclosporin (CyA) in the treatment of severe recalcitrant atopic eczema (AE) in children | Clinical Trial | King’s College London and Guy’s and St. Thomas’ NHS Foundation Trust | Academic - Investigator Led |
EASE | Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow-up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa | Clinical Trial | Amryt | Industry Sponsored |
BADBIR | British Association of Dermatologists Biologic Interventions Register | Non-Interventional Study | University of Manchester | Academic - Collaborative Group |
AD Real World | A Real World Evaluation to Describe Resource Use for the Management of Moderate to Severe Atopic Dermatitis in Secondary Care for Children and Adolescents Aged 6 to 17 in the Republic of Ireland | Non-Interventional Study | Sanofi | Industry Sponsored |
VAD | Understanding T-Cell Immunity in Atopic Dermatitis Patients: Relevance to Staphylococcal Aureus Vaccine Design | Non-Interventional Study | ||
MEASURE AD | Global Cross-Sectional Burden-of- Illness Study in Adolescent and Adult Patients with Atopic Dermatitis. | Non-Interventional Study | AbbVie | Industry Sponsored |
EPIK-P1 | Retrospective Chart Review Study of Patients with PIK3CA- Related Overgrowth Spectrum (PROS) who have received alpelisib as part of a compassionate use program. | Non-Interventional Study | Novartis | Industry Sponsored |
Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
---|---|---|---|---|
Eczema & Food Allergy | Identification of Major Susceptibility Genes for Eczema and Food Allergy | Non-Interventional Clinical Trial | ||
Whole Exome Sequencing | Whole exome screening and next generation sequencing | Non-Interventional Study | University of Dundee | Academic-Investigator Led |
Regional Filaggrin | A Study to Investigate Regional Filaggrin Expression | Non-Interventional Study | ||
DS107E-05 | A prospective, randomised, vehicle-controlled, double-blind, exploratory clinical trial to assess the efficacy and steroid sparing potential of DGLA cream topically applied to early childhood patients with moderate to severe atopic dermatitis | Clinical Trial | Afimmune | Industry Sponsored |
Overgrowth genetics projects | Clinical and molecular characterization of PIK3Kinase related Overgrowth Syndromes | Non-Interventional Study | Cambridge University | Academic-Investigator Led |
Vascular malformation projects | Clinical and molecular characterization of hyperkeratotic vascular malformations | Non-Interventional Study | Université Catholique de Louvain | Academic-Investigator Led |
Inflazome CAPS | MCC950 and derivatives in CAPS patients | Non-Interventional Study | Inflazome Ltd / Trinity College Dublin | Academic - Investigator Led |
PRiTI | Clinical, immunologic and microbiologic characterisation of early onset atopic eczema: A study to identify factors in disease initiation, severity, flare and resolution. | Non-Interventional Study | ||
APPLES | A prospective paediatric study to assess the long-term safety of tacrolimus ointment for the treatment of atopic dermatitis. | Non-Interventional Clinical Trial | Astellas Pharma | Industry Sponsored |
ARQ-092 | A Phase 1/2 Study of ARQ 092 in Patients With Overgrowth Diseases and Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway | Clinical Trial | Arqule | Industry Sponsored |
Alan is a former Section Editor of the Journal of Investigative Dermatology and an Associate Editor of Allergy, and was the Lead Editor of the 3rd Edition of Harper’s Textbook of Pediatric Dermatology (2011). He is an Honorary Professor in the School of Life Sciences, University of Dundee. In 2016 he was awarded a DSc from Queens University Belfast in recognition of his skin barrier research.
Alan’s international awards include: 2006/2007 Paul Gerson Unna Prize from the German Dermatology Society, 2013 Jerry Dolovich Memorial Lecture (AAAAI), 2015 Dr Sydney Watson Smith Lecture (Royal College of Physicians of Edinburgh), 2016 RW Goltz Memorial Lecture (University of Minnesota).
Other positions and responsibilities: